In conclusion, data from the large multicenter GEN-COVID study allow us to define the prevalence of ADAMTS13 mutations in a SARS-CoV-2-positive population and to establish the severity of COVID-19 pathology in patients carrying the mutation. This evidence concerns the gene ADAMTS13 and COVID-19.